Astellas commits up to $300m in Ambrx ADC deal
This article was originally published in Scrip
Astellas Pharma will pay Ambrx up to $300 million in upfront and milestone fees to access the San Diego-based company's antibody-drug conjugate (ADC) technology for the discovery and development of oncology therapies directed at undisclosed targets.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.